WO1999064450A3 - Cif130 inhibits cell cycle progression - Google Patents

Cif130 inhibits cell cycle progression Download PDF

Info

Publication number
WO1999064450A3
WO1999064450A3 PCT/US1999/013143 US9913143W WO9964450A3 WO 1999064450 A3 WO1999064450 A3 WO 1999064450A3 US 9913143 W US9913143 W US 9913143W WO 9964450 A3 WO9964450 A3 WO 9964450A3
Authority
WO
WIPO (PCT)
Prior art keywords
cif130
cell cycle
cycle progression
expression
inhibits cell
Prior art date
Application number
PCT/US1999/013143
Other languages
French (fr)
Other versions
WO1999064450A2 (en
Inventor
Joerg Kaufmann
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to AU44344/99A priority Critical patent/AU4434499A/en
Priority to EP99927444A priority patent/EP1078059A2/en
Publication of WO1999064450A2 publication Critical patent/WO1999064450A2/en
Publication of WO1999064450A3 publication Critical patent/WO1999064450A3/en
Priority to US10/147,268 priority patent/US6589745B2/en
Priority to US10/338,279 priority patent/US20030113791A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A human gene termed CIF130 and its expression products can alter the spatial or temporal patterns of mitosis or cell cycle progression of a human cell. Methods of treating disorders involving alterations in the regulation of mitosis or cell cycle progression utilize the gene and its expression product. Genes whose expression is dependent upon CIF130 expression can be identified.
PCT/US1999/013143 1998-06-12 1999-06-11 Cif130 inhibits cell cycle progression WO1999064450A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU44344/99A AU4434499A (en) 1998-06-12 1999-06-11 Cif130 inhibits cell cycle progression
EP99927444A EP1078059A2 (en) 1998-06-12 1999-06-11 Cif130 inhibits cell cycle progression
US10/147,268 US6589745B2 (en) 1998-06-12 2002-05-15 CIF130 inhibits cell cycle progression
US10/338,279 US20030113791A1 (en) 1998-06-12 2003-01-07 CIF130 inhibits cell cycle progression

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8919898P 1998-06-12 1998-06-12
US60/089,198 1998-06-12
US11163698P 1998-12-09 1998-12-09
US60/111,636 1998-12-09

Publications (2)

Publication Number Publication Date
WO1999064450A2 WO1999064450A2 (en) 1999-12-16
WO1999064450A3 true WO1999064450A3 (en) 2000-02-03

Family

ID=26780343

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013143 WO1999064450A2 (en) 1998-06-12 1999-06-11 Cif130 inhibits cell cycle progression

Country Status (4)

Country Link
US (4) US6303372B1 (en)
EP (1) EP1078059A2 (en)
AU (1) AU4434499A (en)
WO (1) WO1999064450A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1078059A2 (en) 1998-06-12 2001-02-28 Chiron Corporation Cif130 inhibits cell cycle progression
US7056411B2 (en) * 2001-11-05 2006-06-06 The Procter & Gamble Company Variable stretch composites and methods of making the composite
US20070178127A1 (en) * 2006-01-31 2007-08-02 Gowan Company, L.L.C. Agrochemical bird repellent and method
JP2010540534A (en) 2007-09-28 2010-12-24 イントレキソン コーポレーション Therapeutic gene switch constructs and bioreactors for the expression of biotherapeutic molecules and uses thereof
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
WO2012148432A1 (en) 2011-04-28 2012-11-01 Acme Specialty Products, Llc Taste masking compositions and edible forms thereof
JP2018517892A (en) 2015-04-10 2018-07-05 アプライド プロテオミクス，インク． Protein biomarker panel to detect colorectal cancer and advanced adenoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033985A2 (en) * 1997-12-30 1999-07-08 Chiron Corporation C1F150/hTAFII150 IS NECESSARY FOR CELL CYCLE PROGRESSION

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1078059A2 (en) 1998-06-12 2001-02-28 Chiron Corporation Cif130 inhibits cell cycle progression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033985A2 (en) * 1997-12-30 1999-07-08 Chiron Corporation C1F150/hTAFII150 IS NECESSARY FOR CELL CYCLE PROGRESSION

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KAUFMANN J ET AL: "CIF, an essential cofactor for TFIID-dependent initiator function", GENES AND DEVELOPMENT,US,COLD SPRING HARBOR, NY, vol. 10, no. 7, 1 April 1996 (1996-04-01), pages 873 - 886, XP002106713, ISSN: 0890-9369 *
KAUFMANN J ET AL: "CIF150, a human cofactor for transcription factor IID-dependent initiator function", MOLECULAR AND CELLULAR BIOLOGY,US,WASHINGTON, DC, vol. 18, no. 1, 1998, pages 233 - 239, XP002106714, ISSN: 0270-7306 *
SUK ET AL.: "A novel human cDNA homologous to RNA helicase genes", EMBL SEQUENCE DATABASE, 1 November 1998 (1998-11-01), HEIDELBERG DE, XP002123006 *
SUKEGAWA ET AL.: "A putative mammalian RNA helicase with arginine-serine-rich domain colocalizes with a splicing factor", EMBL SEQUENCE DATABASE, 1 November 1996 (1996-11-01), HEIDELBERG DE, XP002123005 *
SUKEGAWA ET AL.: "A putative mammalian RNA helicase with arginine-serine-rich domain colocalizes with a splicing factor", J. BIOL. CHEM., vol. 270, 1995, pages 15702 - 15706 *

Also Published As

Publication number Publication date
US20020143154A1 (en) 2002-10-03
US6589745B2 (en) 2003-07-08
AU4434499A (en) 1999-12-30
US20030113791A1 (en) 2003-06-19
EP1078059A2 (en) 2001-02-28
US6423822B1 (en) 2002-07-23
US6303372B1 (en) 2001-10-16
WO1999064450A2 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
HUP9800033A3 (en) Compositions for the treatment of dermatological disorders and methods for their use
DE69421100T2 (en) TREATMENT OF HEAVY FINAL PRODUCTS OF THE FISCHER-TROPSCH PROCESS
ZA967182B (en) Asthma associated factors as targets for treating atopic allergies including asthma and related disorders.
NO991951L (en) Tienopyrimidines with phosphodiesterase V inhibitory effect
PL327312A1 (en) Tricyclic amides useful in inhibiting action of g protecin and in treatment of poliferation-type diseases
DE69619831T2 (en) ABSORBENT ARTICLE WITH IMPROVED DRY IN THE WAIST AREA AND PRODUCTION PROCESS
EP0820467A4 (en) Methods of treating disorders of the eye
GB2301363B (en) Human phosphodiesterase type ivc and its production and use
HUP0003298A3 (en) Branched chain fatty acids, their derivatives and use in the treatment of central nervous system disorders
GB2270919B (en) Aqueous wax and silicone dispersions,their production and use
ZA964762B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
WO1999064450A3 (en) Cif130 inhibits cell cycle progression
ZA964761B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
AP9100259A0 (en) Azabenzimidazoles in the treatment of asthma,arthritis and related diseases
GB2293604B (en) Dermal fibroblast cells containing muscle-specific DNA and the use of dermal fibroblast cells in the treatment of muscular disorders
GB2306909B (en) Moulded articles their production and use
CA95616S (en) Tanned hide
HUP9900735A3 (en) Methods of producing aminophenylsulphonyl carbamides and intermediate products for use in the process
EP0745597A3 (en) Novel melatonergic indanyl piperazines or homopiperazines
IL148668A0 (en) Derivatives of 1,3-cyclic propandiol phosphate and their action in differentiation therapy
AU3737500A (en) Method of preventing the death of retinal neurons and treating ocular diseases
WO1999033985A3 (en) C1F150/hTAFII150 IS NECESSARY FOR CELL CYCLE PROGRESSION
MXPA02004704A (en) Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders.
ZA946989B (en) Alkanediamine derivatives and their use in the treatment of arrhythmia and ischaemic rhythm disorders
AU6984696A (en) Pyrrolyl tetrahydroquinoxalin diones, their production and use in the treatment of diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09332295

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09709979

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999927444

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999927444

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10147268

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 10338279

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999927444

Country of ref document: EP